Commonly altered pathways in high MR1-expressing gliomas involve antigen presentation and T-cell activation, which could influence an immunosuppressive tumor microenvironment,13 by altering the T-cell and NK cell function, possibly resulting in decreased tumor clearance and an ineffective antitumor immune response. The gene discussed is MR1; the disease is central nervous system cancer.